Daxor (DXR) Q2 2026 earnings summary

Executive summary

• Achieved FDA clearance for next-generation analyzer, secured a new patent, completed acquisition of Isotex Diagnostics, and executed a $9 million capital raise to support growth initiatives.

• Focused on expanding commercial team and infrastructure, with kit sales up 16% year-over-year in H1 2026.

• Transitioned regulatory reporting to reflect shift from investment company to medical diagnostics and technology operations.

Financial highlights

• Net assets increased to $51.83 million as of June 30, 2026, up from $45.89 million at December 31, 2025.

• Net asset value (NAV) per share was $8.88 at June 30, 2026, compared to $9.07 at year-end 2025.

• Completed $9 million registered direct offering in January 2026 at $11.75 per share, accretive to NAV.

• No outstanding debt as of June 30, 2026; retired $1.17 million in short-term debt during the period.

• Stock-based compensation expense totaled $972,993 for the six months ended June 30, 2026.

Outlook and guidance

• Expectation of accelerated kit sales growth in H2 2026 and into 2027 as expanded sales team ramps up.

• Anticipate increased placements of next-generation BVA systems, with over fifteen indications of interest from hospitals and practices.

• Continued investment in manufacturing capacity and inventory to support commercial expansion.